Cancer

News

AZ/Merck & Co's Lynparza delays spread of pancreatic cancer

AstraZeneca and Merck & Co’s Lynparza could offer a new option for certain patients with pancreatic cancer after a trial showed it slowed progression of the disease.

News

Bayer takes control of Loxo duo as Lilly closes takeover

Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an

News

Bayer/Orion showcase results from prostate cancer challenger

Bayer and development partner Orion have released detailed results from the trial that will form the backbone of its filing for their latest prostate cancer drug, as they aim to take on two

News

Merck's Keytruda gets boost in kidney and head and neck canc...

Merck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Bristol-Myers Squibb, with positive results in kidney cancer, and the promise of an F

News

Grey Wolf raises £10m for tumour 'illumination' tech

Immuno-oncology biotech Grey Wolf Therapeutics has raised £10 million in series A financing to develop therapies that increase tumour visibility.

News

GSK bolts-on immuno-oncology candidate with €3.7bn Merck dea...

GlaxoSmithKline is making another big play in cancer, signing a wide-ranging deal with Merck KGaA for M7824, an immuno-oncology drug that made a splash at last year’s ESMO meeting.

AZ/Merck & Co's Lynparza delays spread of pancreatic cancer

Bayer takes control of Loxo duo as Lilly closes takeover

Bayer/Orion showcase results from prostate cancer challenger

Merck's Keytruda gets boost in kidney and head and neck canc...

Grey Wolf raises £10m for tumour 'illumination' tech

GSK bolts-on immuno-oncology candidate with €3.7bn Merck dea...

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks